Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial ... Biopharmaceuticals, Neurology, Acquisitions Mylan, Mapi Pharma, GA Depot, Glatiramer, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news